Difference between revisions of "Medicines for children"
STUART KING (talk | contribs) |
STUART KING (talk | contribs) |
||
| Line 1: | Line 1: | ||
An intergal practice of the European Commission's pharmaceutical unit is to ensure a good quality of medicinal products for paedriatic use. In response to the incidence of inadequate medicines for children in Europe, the European Commission implemented a proposal on the 29th September 2004. Additionally this legislation seeks to promote the development of paediatric medicines, whereby at the national scale of EU member states have a role to play in providing national incentives for the research and development of such pharmaceuticals. <ref> Regulation on medicines for children http://ec.europa.eu/enterprise/pharmaceuticals/paediatrics/docs/paeds_qa_october_28.pdf Accessed 1/03/08 </ref> | An intergal practice of the European Commission's pharmaceutical unit is to ensure a good quality of medicinal products for paedriatic use. In response to the incidence of inadequate medicines for children in Europe, the European Commission implemented a proposal on the 29th September 2004. Additionally this legislation seeks to promote the development of paediatric medicines, whereby at the national scale of EU member states have a role to play in providing national incentives for the research and development of such pharmaceuticals. <ref> Regulation on medicines for children http://ec.europa.eu/enterprise/pharmaceuticals/paediatrics/docs/paeds_qa_october_28.pdf Accessed 1/03/08 </ref> | ||
| + | |||
| + | ==Notes== | ||
| + | |||
| + | <references/> | ||
Revision as of 23:19, 3 March 2008
An intergal practice of the European Commission's pharmaceutical unit is to ensure a good quality of medicinal products for paedriatic use. In response to the incidence of inadequate medicines for children in Europe, the European Commission implemented a proposal on the 29th September 2004. Additionally this legislation seeks to promote the development of paediatric medicines, whereby at the national scale of EU member states have a role to play in providing national incentives for the research and development of such pharmaceuticals. [1]
Notes
- ↑ Regulation on medicines for children http://ec.europa.eu/enterprise/pharmaceuticals/paediatrics/docs/paeds_qa_october_28.pdf Accessed 1/03/08
